从花知晓到圣诺医药,中国美妆资本在押注什么未来?

蓝鲸财经
Sep 17

文|未来迹FBeauty9月,中国美妆资本圈接连传来两则重磅消息:华熙生物通过香港全资子公司斥资约1.38亿港元,认购圣诺医药9.44%股权;珀莱雅则以独家投资者身份完成对花知晓的B轮融资。华熙生物把这笔投资定义为“生命科学与医美融合”的战略落子,而珀莱雅则直指“供应链、渠道与内容赋能”。这两笔投资,释放出两大关键信号:其一,头部资本正持续押注“前沿技术+医美”赛道(华熙→小核酸/医药);其二,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10